2022 will probably continue the trends that shaped medtech investment and deal-making in 2021, according to a detailed analysis of the upcoming expected investment trends in KPMG’s 2022 Healthcare and Life Sciences Investment Outlook.
Last year, Medtech Insight spoke to Kristin Pothier, a health care and life sciences deal advisory and strategy leader at KPMG, to hear a reflection on 2020’s deal making and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?